Schwarz, Caroline
Bauer, David
Dorn, Livia
Jachs, Mathias
Hartl, Lukas
Chromy, David
Weseslindtner, Lukas
Pfisterer, Nikolaus
Hennlich, Barbara
Stückler, Annika
Strassl, Robert
Voill-Glaninger, Astrid
Hübl, Wolfgang
Willheim, Martin
Köhrer, Karin
Jansen-Skoupy, Sonja
Tomez, Sabine
Krugluger, Walter
Madl, Christian
Schwarz, Michael
Balcar, Lorenz
Semmler, Georg
Brinkmann, Leonard
Burghart, Lukas
Antonitsch, Lukas
Weidinger, Gerhard
Riedl, Florian
Laferl, Hermann
Kurteva, Vesselina
Traugott, Marianna
Hind, Julian
Wenisch, Christoph
Aburaia, Abdelrahman
Sebesta, Christian
Schmid, Daniela
Rothweiler, Sonja
Remetic, Jelena
Gschwantler, Michael
Maieron, Andreas
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Funding for this research was provided by:
Gilead Sciences
Medical University of Vienna
Article History
Received: 28 May 2023
Accepted: 23 August 2023
First Online: 29 September 2023
Declarations
:
: C. Schwarz received travel support from Gilead, Abbvie, and Gebro; speaking honoraria from Abbvie and Gilead; and payments for consulting from Gilead. D. Bauer received travel support from Gilead and AbbVie; speaking honoraria from AbbVie and Siemens and grant support from Gilead and AbbVie. M. Jachs served as a speaker and/or consultant for Gilead Sciences. D. Chromy served as a speaker and/or consultant and/or advisory board member for AbbVie, Gilead, and MSD, and received travel support from AbbVie, MSD, ViiV Healthcare, and Gilead. M. Schwarz received travel support from MSD, Sandoz, BMS, Abbvie and Gilead; and speaking honoraria from BMS. L. Brinkmann received travel support from Merck Sharp & Dohme, Astro Pharma GmbH. J. Remetic: Employee of Gilead Sciences. M. Gschwantler received grant support from Abbvie, Gilead, and MSD; speaking honoraria from Abbvie, Gilead, Janssen, Roche, Intercept, and MSD; consulting/advisory board fees from Abbvie, Gilead, Janssen, Roche, Intercept, Norgine, AstraZeneca, Falk, Shionogi and MSD; and travel support from Abbvie and Gilead. A. Maieron received grant support from Abbvie and Gilead; speaking honoraria from Abbvie, Gilead, Janssen, Roche, Intercept, and MSD; consulting/advisory board fees from Abbvie, Gilead, Janssen, Roche, Intercept, Norgine, and MSD; and travel support from Abbvie, Gilead and Roche. T. Reiberger received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead, and Roche. L. Dorn, L. Hartl, L. Weseslindtner, N. Pfisterer, B. Hennlich, A. Stückler, R. Strassl, A. Voill-Glaninger, W. Hübl, M. Willheim, K. Köhrer, S. Jansen-Skoupy, S. Tomez, W. Krugluger, C. Madl, L. Balcar, G. Semmler, L. Burghart, L. Antonitsch, G. Weidinger, F. Riedl, H. Laferl, V. Kurteva, M. Traugott, J. Hind, C. Wenisch, A. Aburaia, C. Sebesta, D. Schmid and S. Rothweiler declare that they have no competing interests.
: All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. The data collection in this study was approved by the respective ethics committees of the Medical University of Vienna (EK#1968/2018), the ethics committee of the city of Vienna (EK#19-175-VK), and the ethics committee for the State of Lower Austria (EK#GS1-EK-4/624-2019).